Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 701–800 of 1,001
Molecular structures guide the engineering of chromatin
Tekel, S. J., & Haynes, K. A. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx531 · Cited by 23
“Bromodomain inhibitors such as JQ1 (120) and I-BET (121) have been identified in high throughput screens to identify small compounds that fit the histone recognition pocket of BRD2 (1- 473), BRD3 (1-434) and BRD4 (1-477) (121).”
BackgroundInfluentialSuh, J. L., Watts, B. E., Stuckey, J. I., Norris-Drouin, J. L., Cholensky, S. H., Dickson, B. M., An, Y., Mathea, S., Salah, E., Knapp, S., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00150 · Cited by 21
Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase – 6 Inhibitors
Ružić, D., Petković, M., Agbaba, D. D., Ganesan, A., & Nikolic, K. M. (2019) · Molecular Informatics · doi:10.1002/minf.201800083 · Cited by 21
Yang, L., Liu, Y., Fan, M., Zhu, G., Jin, H., Liang, J., Liu, Z., Huang, Z., & Zhang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111656 · Cited by 23
Structure‐Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases
Małecki, P. H., Rüger, N., Roatsch, M., Krylova, O. O., Link, A., Jung, M., Heinemann, U., & Weiss, M. S. (2019) · ChemMedChem · doi:10.1002/cmdc.201900441 · Cited by 21
Pelascini, L. P. L., Maggio, I., Liu, J., Holkers, M., Cathomen, T., & Gonçalves, M. A. F. V. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.107 · Cited by 23
“Although HDAC inhibitors entering phases I and II clinical trials are targeting an increasing number of conditions, the majority of them are directed at life-threatening diseases (Arrowsmith et al. , 2012).”
Regulation of CD4 T‐cell differentiation and inflammation by repressive histone methylation
Antignano, F., & Zaph, C. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2014.115 · Cited by 23
Amprazi, M., Kotsifaki, D., Providaki, M., Kapetaniou, E. G., Fellas, G., Kyriazidis, I., Pérez, J., & Kokkinidis, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322065111 · Cited by 21
“Additionally, the prevalence of coiled-coils and helical bundles in secretion systems of pathogenic bacteria (40) or in members of epigenetic protein families that represent new frontiers for drug discovery (41) makes our results relevant to the”
BackgroundFarias, N. D., de Oliveira, N. F. P., & da Silva, P. M. (2017) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2017.08.007 · Cited by 22
Nam, G., Jung, J. M., Park, H., Baek, S. Y., Baek, K. S., Mok, H. Y., Kim, D. E., & Jung, Y. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.06.036 · Cited by 21
Subramanian, K., Hutt, D. M., Scott, S. M., Gupta, V. R., Mao, S., & Balch, W. E. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010524 · Cited by 22
“However, HDACi also regulate the acetylation of nonhistone proteins (111), which can impede the ubiquitination of lysine residues, thereby altering protein stability, and modulating the activity of protein products by altering their ability to interact with substrates and regulatory proteins (125).”
BackgroundKonigsberg, I. R., Maier, L. A., & Yang, I. V. (2021) · European Respiratory Review · doi:10.1183/16000617.0076-2021 · Cited by 23
Geurs, S., Clarisse, D., Baele, F., Franceus, J., Desmet, T., Bosscher, K. D., & D’hooghe, M. (2022) · Chemical Communications · doi:10.1039/d2cc01550a · Cited by 20
Pushing the boundaries: future directions in the management of spinal muscular atrophy
Moultrie, F., Chiverton, L., Butler, I., Lilien, C., & Servais, L. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.12.006 · Cited by 20
Yang, L., Liang, Q., Shen, K., Ma, L., An, N., Deng, W., Fei, Z., & Liu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.02.019 · Cited by 20
Epigenetics and the IRFs: A complex interplay in the control of immunity and autoimmunity
Rogatsky, I., Chandrasekaran, U., Manni, M., Yi, W., & Pernis, A. B. (2013) · Autoimmunity · doi:10.3109/08916934.2013.853050 · Cited by 20
“code) and of ‘‘readers’’ such as bromodomain-containing proteins (that bind to histone modifications and thus ‘‘read’’ the code) enables histone acetylation to become an integrating point for diverse sets of environmental cues and thus plays a fundamental role in the tight and dynamic control of gene expression [28,30…”
BackgroundVellore, N. A., & Baron, R. (2013) · BMC Biophysics · doi:10.1186/2046-1682-6-15 · Cited by 21
“Lysine Specific Demethylase-1 (LSD1) is an epigenetic target of outstanding interest for the discovery of drugs against cancer [1-6] and neurodegenerative disorders [7].”
Yue, L., Du, J., Ye, F., Chen, Z., Li, L., Lian, F., Zhang, B., Zhang, Y., Jiang, H., Chen, K., et al. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01248e · Cited by 20
Epigenetics and aging research: Between adult malleability and early life programming
Müller, R., & Samaras, G. (2018) · BioSocieties · doi:10.1057/s41292-017-0091-y · Cited by 23
“Epigenetic processes such as methylation and acetylation are considered to work with ‘‘a large number of druggable proteins that mediate their dynamic activity’’ (Arrowsmith et al, 2012, p. 385; emphasis ours).”
BackgroundRygiel, K., & Bułaś, L. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_403_17 · Cited by 21
The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy
Bertrand, P., Blanquart, C., & Héroguez, V. (2019) · Biomolecules · doi:10.3390/biom9020060 · Cited by 21
“In the field of biology, the last two decades have seen the dawn of the epigenetic strategy [1,2].”
BackgroundPathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers
Kumar, A., Kumari, N., Nallabelli, N., & Prasad, R. (2019) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-019-00828-x · Cited by 21
EpiDBase: a manually curated database for small molecule modulators of epigenetic landscape
Loharch, S., Bhutani, I., Jain, K., Gupta, P. K., Sahoo, D. K., & Parkesh, R. (2015) · Database · doi:10.1093/database/bav013 · Cited by 20
Oudhoff, M. J., Antignano, F., Chenery, A., Burrows, K., Redpath, S. A., Braam, M. J. S., Perona‐Wright, G., & Zaph, C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005876 · Cited by 23
“Lysine methyltransferases represent part of a family of novel druggable targets that are currently being investigated for a variety of diseases [16].”
BackgroundAllosteric Regulation of Epigenetic Modifying Enzymes
Zucconi, B. E., & Cole, P. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.015 · Cited by 15
“The Jmj enzymes require iron(II) and a-ketoglutarate as cofactors [1,2,29].”
BackgroundBreast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities
Esparza‐López, J., Escobar-Arriaga, E., Soto-Germes, S., & Ibarra-Sánchez, M. D. J. (2017) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.17002177 · Cited by 32
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors
Labadie, S. S., Dragovich, P. S., Cummings, R. T., Deshmukh, G. S., Gustafson, A. E., Han, N., Harmange, J.-C., Kiefer, J. R., Li, Y., Liang, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.070 · Cited by 19
Wu, S., Wang, L., Sun, H. B., Wang, W., & Yu, Y. X. (2020) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2020.1777584 · Cited by 19
“BRDs are present in 46 diverse proteins and are classified into eight different subfamilies [6,7].”
BackgroundFragment-Based Identification of Ligands for Bromodomain-Containing Factor 3 of Trypanosoma cruzi
Laurin, C. M. C., Bluck, J. P., Chan, A., Keller, M., Boczek, A., Scorah, A. R., See, K. F. L., Jennings, L. E., Hewings, D. S., Woodhouse, F., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00618 · Cited by 19
Fli1 + cells transcriptional analysis reveals an Lmo2–Prdm16 axis in angiogenesis
Matrone, G., Xia, B., Chen, K., Denvir, M. A., Baker, A. H., & Cooke, J. P. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008559118 · Cited by 20
Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
Yang, Q., Falahati, A., Khosh, A., Mohammed, H., Kang, W., Corachán, A., Bariani, M. V., Boyer, T., & Al-Hendy, A. A. (2022) · Cells · doi:10.3390/cells11233801 · Cited by 20
A scintillation proximity assay for histone demethylases
Yu, W., Eram, M. S., Hajian, T., Szykowska, A., Burgess-Brown, N., Vedadi, M., & Brown, P. J. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.06.023 · Cited by 19
“There are at least 60 protein methyltransferases (PMTs) encoded in the human genome, including 51 lysine methyltransferases (PKMTs) and 9 protein arginine methyltransferases (PRMTs) [1].”
BackgroundAn azumamide C analogue without the zinc-binding functionality
Villadsen, J. S., Kitir, B., Wich, K., Friis, T., Madsen, A. S., & Olsen, C. A. (2014) · MedChemComm · doi:10.1039/c4md00252k · Cited by 20
Roatsch, M., Robaa, D., Pippel, M., Nettleship, J. E., Reddivari, Y., Bird, L. E., Hoffmann, I., Franz, H., Owens, R. J., Schüle, R., et al. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.15.188 · Cited by 19
LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer
Jotatsu, T., Yagishita, S., Tajima, K., Takahashi, F., Mogushi, K., Hidayat, M., Wirawan, A., Ko, R., Kanemaru, R., Shimada, N., et al. (2016) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.11.015 · Cited by 19
Structural Characterization of the SMRT Corepressor Interacting with Histone Deacetylase 7
Desravines, D. C., Martin, I. S., Schneider, R., Mas, P. J., Aleksandrova, N., Jensen, M. R., Blackledge, M. J., & Hart, D. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-03718-5 · Cited by 20
Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains
Millan, D. S., Kayser-Bricker, K. J., Martin, M. W., Talbot, A. C., Schiller, S., Herbertz, T., Williams, G. L., Luke, G. P., Hubbs, S. E., Morales, M. A. A., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00191 · Cited by 19
Osuna-Luque, J., Rodríguez‐Ramos, Á., Gámez-del-Estal, M. M., & Ruiz‐Rubio, M. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518798628 · Cited by 23
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors
Geng, A., Hao, C., Zhang, L., Chen, X., Li, H., Lu, T., & Zhu, Y. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.047 · Cited by 20
Yu, H. T., He, J., Liu, W., Feng, S., Gao, L., Xu, Y., Zhang, Y., Hou, X., Zhou, Y., Yang, L., et al. (2021) · Hepatology · doi:10.1002/hep.31870 · Cited by 22
Global analysis of lysine acetylation in soybean leaves
Li, G., Zheng, B., Zhao, W., Ren, T., Zhang, X., Ning, T., & Liu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-97338-9 · Cited by 21
Lee, Y., Gibbons, G. S., Lee, S. Y., Nikolovska‐Coleska, Z., & Dou, Y. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.02.007 · Cited by 19
“Abnormal regulation of epigenetic events leads to numerous human diseases including neurodegeneration, metabolic disorders and cancers [1].”
BackgroundAn updated map of Trypanosoma cruzi histone post-translational modifications
de Almeida, R. F., Fernandes, M., & de Godoy, L. M. F. (2021) · Scientific Data · doi:10.1038/s41597-021-00818-w · Cited by 19
Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers
Chen, Q., Peng, K., Mo, P., & Yu, C. (2022) · Cancers · doi:10.3390/cancers14122841 · Cited by 19
“There is a relatively large lysine methyltransferase family [12]; however, the same type of methylation modification cannot be catalyzed by all enzymes, which have substrate sequence preference.”
BackgroundTargeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy
Zheng, T., Wang, S., Liu, W., & Lu, Y. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02613 · Cited by 19
Su, J., Qiu, Y., Ma, K., Yao, Y., Wang, Z., Li, X., Zhang, D., Tu, Z., & Jiang, S. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.05.078 · Cited by 18
Sun, Q., Yao, Y., Liu, C., Li, H., Yao, H., Xue, X., Liu, J., Tu, Z., & Jiang, S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.102 · Cited by 18
Studying epigenetic complexes and their inhibitors with the proteomics toolbox
Weigt, D., Hopf, C., & Médard, G. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0244-z · Cited by 19
“Even though many proteins involved in each of the tasks have been identified, epigenetic regulation occurs on the level of more complex protein interactions, which has gained rising interest during the past decade [60].”
BackgroundZipin‐Roitman, A., Aqaqe, N., Yassin, M., Biechonski, S., Amer, M., van Delft, M. F., Gan, O. I., McDermott, S., Buzina, A., Ketela, T. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15147 · Cited by 19
“In pursuance of a candidate gene that can overcome this SMYD2 knock-down mediated growth arrest we analyzed the expression of several KMTs with the similar structural and functional features to SMYD2 [39].”
BackgroundMapping of Drug-like Chemical Universe with Reduced Complexity Molecular Frameworks
Kontijevskis, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00006 · Cited by 22
Ding, H., Lu, W., Hu, J., Liu, Y., Zhang, C., Lian, F., Zhang, N., Meng, F., Luo, C., & Chen, K. (2018) · Molecules · doi:10.3390/molecules23030567 · Cited by 18
Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay
Song, Y., Li, L., Chen, Y., Liu, J., Xiao, S.-H., Lian, F., Zhang, N., Ding, H., Zhang, Y., Chen, K., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.020 · Cited by 18
Wang, Q., An, X., Xu, J., Wang, Y., Liu, L., Leung, E. L., & Yao, X. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01526k · Cited by 19
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Vaca, H. R., Celentano, A. M., Toscanini, M. A., Heimburg, T., Ghazy, E., Zeyen, P., Hauser, A., Oliveira, G., Elissondo, M. C., Jung, M., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009226 · Cited by 21
Finding Druggable Sites in Proteins Using TACTICS
Evans, D. J., Yovanno, R. A., Rahman, S., Cao, D. W., Beckett, M. Q., Patel, M. H., Bandak, A. F., & Lau, A. Y. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00204 · Cited by 20
P300/CBP-Associated Factor Activates Cardiac Fibroblasts by SMAD2 Acetylation
Lim, Y., Jeong, A., Kwon, D., Lee, Y.-U., Kim, Y., Ahn, Y., Kook, T., Park, W.-J., & Kook, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189944 · Cited by 18
“Readers, on which less research has been done, possess unique domains that recognize the specific PTM status of the histones and are recruited to specific covalent “marks” on histones, which then relay the signals from the histones to the other parts of the cells [15].”
BackgroundDeciphering the epigenetic code of T lymphocytes
Allan, R. S., & Nutt, S. L. (2014) · Immunological Reviews · doi:10.1111/imr.12207 · Cited by 19
Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes
Andreoli, F., & Río, A. D. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.04.007 · Cited by 18
“Different studies elucidate the impact that PTMs have on chromatin and their relevance in human physiology and pathology [16,18,25,26, 31,51 – 57].”
BackgroundGenome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma
Parris, T. Z., Rönnerman, E. W., Engqvist, H., Biermann, J., Truvé, K., Nemes, S., Forssell-Aronsson, E. B., Solinas, G., Kovács, A., Karlsson, P., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25329 · Cited by 20
“Although recent reports have shown that protein methyltransferases can be targeted with small-molecule inhibitors, none are currently used in clinical practice [26, 32, 33].”
BackgroundAn epi(c)genetic war: Pathogens, cancer and human genome
Rajagopalan, D., & Jha, S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.003 · Cited by 20
Oligomerization and Auto-methylation of the Human Lysine Methyltransferase SETD6
Weil, L. E., Shmidov, Y., Kublanovsky, M., Morgenstern, D., Feldman, M., Bitton, R., & Levy, D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.08.028 · Cited by 17
LSD1 inhibition circumvents glucocorticoid-induced muscle wasting of male mice
Cai, Q., Sahu, R., Ueberschlag-Pitiot, V., Souali‐Crespo, S., Charvet, C., Silem, I., Cottard, F., Ye, T., Taleb, F., Metzger, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47846-9 · Cited by 24
“Extended figure 3C-fiber cross-section area (CSA) of GR(i)skm-/- mice starved for 48 h is much higher than the GR(i)skm-/- mice fed animals, which I feel is impossible.”
Mal, S., Majumder, D., Birari, P., Sharma, A. K., Gupta, U. D., Jana, K., Kundu, M., & Basu, J. (2024) · FEBS Letters · doi:10.1002/1873-3468.15001 · Cited by 18
“SIRTs belong to the class III histone deacetylases (HDACs) [3].”
Neuroepigenomics: resources, obstacles, and opportunities
Satterlee, J. S., Beckel-Mitchener, A. C., Little, A. R., Procaccini, D. C., Rutter, J. L., & Lossie, A. C. (2015) · Neuroepigenetics · doi:10.1016/j.nepig.2014.10.001 · Cited by 18
“velopment (Arrowsmith et al., 2012).”
Chopra, M., & Bohlander, S. K. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.10.005 · Cited by 19
RNAs — Physical and functional modulators of chromatin reader proteins
Hiragami-Hamada, K., & Fischle, W. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.015 · Cited by 20
Redundancy of the genetic code enables translational pausing
D'Onofrio, D. J., & Abel, D. L. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00140 · Cited by 20
“Data sets are found in both the coding and non-coding regions of the DNA (Mercer et al., 2009; Craig and Wong, 2011; Ghanbarian et al., 2011; Derrien et al., 2012; Hunter et al., 2012; Morris, 2012; St. Laurent et al., 2012; Bucher, 2013; Arrowsmith et al., 2012).”
BackgroundEpigenetics Primer: Why the Clinician Should Care About Epigenetics
Duarte, J. D. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1325 · Cited by 19
“In addition to previously approved drugs with recently discovered epigenetic effects, drugs specifically designed to alter epigenetic status have already been approved by the Food and Drug Administration (FDA) (Table 2), with many more being developed.(47) The first examples of FDA-approved epigenetic therapy (fomivir…”
BackgroundSong, H., Niu, X., Quan, J., Li, Y., Yuan, L., Wang, J., Ma, C., & Ma, E. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103679 · Cited by 17
Targeting Epigenetic ‘Readers’ with Natural Compounds for Cancer Interception
Damiani, E., Duran, M., Mohan, N., Rajendran, P., & Dashwood, R. H. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.189 · Cited by 18
“org ifying enzymes to specific sites; (2) chromatin organization modifier (chromodomain, CRD) moieties that interact with trimethylated lysines, resulting in either activation or silencing of gene expression; (3) malignant brain tumor (MBT) domains that recognize mono- and dimethylated lysines on histone H3 and histon…”
BackgroundWang, Y., Wu, S., Wang, L., Yang, Z., Zhao, J., & Zhang, L. (2020) · RSC Advances · doi:10.1039/d0ra09469b · Cited by 17
Blanquart, C., Linot, C., Cartron, P., Tomaselli, D., Mai, A., & Bertrand, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180706105903 · Cited by 19
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia
Montanaro, A., Kitara, S., Cerretani, E., Marchesini, M., Rompietti, C., Pagliaro, L., Gherli, A., Su, A. H., Minchillo, M. L., Caputi, M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05002-5 · Cited by 18
“DISCUSSION Following the recent success of inhibitors of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), some of which are now clinically approved [36], a new wave of epigenetic targeting molecules focused on histone methyltransferase inhibitors have entered clinical investigation.”
BackgroundÇiçek, F. A., Zeynep, T.-K., Özçınar, E., Bozkuş, Y., Can, A. K., & Belma, T. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3392-2 · Cited by 20
“control with DNA binding proteins and non-coding RNAs, and translation control with microRNAs and RNA binding proteins [14].”
BackgroundEpigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets
Lizcano, F., & García, J. (2012) · Pharmaceuticals · doi:10.3390/ph5090963 · Cited by 22
“varieties of cancer that can affect human beings [10–15].”
BackgroundMolecular Structure, Binding Affinity, and Biological Activity in the Epigenome
Zsidó, B. Z., & Hetényi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114134 · Cited by 19
“Besides the effector (reader) proteins, there are also writers, erasers [33,34] and remodelers [21] working in the heart of PTM machinery of the histone code (Figure 2).”
BackgroundWatson, M., Chow, S., Barsyte, D., Arrowsmith, C. H., Shankey, T. V., Minden, M. D., & Hedley, D. W. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22344 · Cited by 17
“” A third class of chromatin-related proteins are “readers” (2).”
BackgroundSelf-citationEpigenetics of Melanoma: Implications for Immune-Based Therapies
Fratta, E., Sigalotti, L., Covre, A., Parisi, G., Coral, S., & Maio, M. (2013) · Immunotherapy · doi:10.2217/imt.13.108 · Cited by 19
Gao, T., Fu, S., Quan, X., Sun, J., Jiang, M., & Li, J. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s566173 · Cited by 21
“1,6,7 Among them, writers catalyze the addition of epigenetic marks, including DNA methyltransferases (DNMTs), histone lysine methyltransferases (KMTs) and histone acetyltransferases (HATs).”
3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine
Xu, R., Chen, R., Tu, C., Gong, X. Y., Liu, Z., Mei, L., Ren, X., & Li, Z. (2023) · Phenomics · doi:10.1007/s43657-023-00111-3 · Cited by 18
“…increasingly important to understand epigenetics (e.g., DNA methylation, post-translational modifications of histones, and non-coding RNA) in virtually all fields of biomedical research (Arrowsmith et al. 2012; Berger et al. 2009; Greer and Shi 2012; Jurkowska et al. 2011; Kooistra and Helin 2012).”
Recent developments in catalysis and inhibition of the Jumonji histone demethylases
Sarah, L., & Fujimori, D. G. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102707 · Cited by 17
“The JMJC domain-containing demethylase family comprises of about 20 human enzymes that are classified into KDM2-8 families [5,12,13].”
BackgroundBhattacharya, S., & Tu, B. P. (2024) · Journal of Cell Science · doi:10.1242/jcs.261250 · Cited by 19
Chromatin Landscape and Endocrine Response in Breast Cancer
Magnani, L., Brunelle, M., Gévry, N. Y., & Lupien, M. (2012) · Epigenomics · doi:10.2217/epi.12.64 · Cited by 17
Zhou, J., Xie, H., Liu, Z., Luo, H., & Wu, R. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500513n · Cited by 18
Strategy to Target the Substrate Binding site of SET Domain Protein Methyltransferases
Nguyen, K. T., Li, F., Poda, G. I., Smil, D. V., Vedadi, M., & Schapira, M. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300596x · Cited by 16
Self-citationTargeting mutant huntingtin for the development of disease-modifying therapy
Appl, T., Kaltenbach, L. S., Lo, D. C., & Terstappen, G. C. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.06.017 · Cited by 18
Singh, A. K., Chandra, N., & Bapat, S. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0505 · Cited by 16
Epigenetic Regulation of ALS and CMT: A Lesson from Drosophila Models
Yamaguchi, M., Omori, K., Asada, S., & Yoshida, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020491 · Cited by 18
“Up- and downregulation of these enzymes play important roles in many pathological processes [87,88].”
BackgroundYoo, M., Park, T. H., Yoo, M., Kim, Y., Lee, J.-Y., Lee, K. M., Ryu, S. E., Lee, B. I., Jung, K.-Y., & Park, C. H. (2021) · Molecules · doi:10.3390/molecules26061686 · Cited by 16
“Most of the histone modifications are performed in three distinct steps: adding; removing; and reading [5,6].”
BackgroundMethodInfluentialSelf-citationDiscovery of a potent and selective inhibitor of histone lysine demethylase KDM4D
Fang, Z. Y., Liu, Y., Zhang, R., Chen, Q., Wang, T., Yang, W. M., Fan, Y. L., Yu, C., Xiang, R., & Yang, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113662 · Cited by 16
Nuclear Mechanisms Involved in Endocrine Resistance
Dittmer, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736597 · Cited by 17
“PTMs are regulated by “writing” enzymes that add a modification and “erasing” enzymes that remove a modification (185).”
BackgroundKushak, R. I., Sengupta, A., & Winter, H. S. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15052 · Cited by 17
“The coiling and uncoiling of these structures facilitates or inhibits DNA replication and repair.(76) Epigenetic mechanisms control which genes are transcribed and which are silenced at any given time.”
BackgroundAhmad, Z., Mir, M. A., Sheikh, B. A., & Bhat, B. A. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666211222164938 · Cited by 18
Recent Advances in Dual BRD4‐Kinase Inhibitors Based on Polypharmacology
Chen, L., Liu, Z., & Li, X. (2022) · ChemMedChem · doi:10.1002/cmdc.202100731 · Cited by 16
Protein Methylation in Diabetic Kidney Disease
Cheng, Y., Chen, Y., Wang, G., Liu, P., Xie, G., Jing, H., Chen, H., Fan, Y., Wang, M., & Zhou, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.736006 · Cited by 19
Alternative Mechanisms for DNA Engagement by BET Bromodomain-Containing Proteins
Kalra, P., Zahid, H., Ayoub, A. M., Dou, Y., & Pomerantz, W. C. K. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00157 · Cited by 16
Hu, X., Zou, Y., Copland, D. A., Schewitz‐Bowers, L. P., Li, Y., Lait, P. J. P., Stimpson, M. L., Zhang, Z., Guo, S., Liang, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104333 · Cited by 17
Nanostructured delivery system for Suberoylanilide hydroxamic acid against lung cancer cells
Renu, S., Selvaraju, K., Natesan, S., Krishnaswami, V., Sonnemann, J., & Ravikumar, V. (2015) · Materials Science and Engineering C · doi:10.1016/j.msec.2015.02.037 · Cited by 16
Marzese, D. M., Witz, I. P., Kelly, D. F., & Hoon, D. S. �. (2015) · Epigenomics · doi:10.2217/epi.15.77 · Cited by 16
Xu, S., Zhou, C., Liu, R., Zhu, Q., Xu, Y., Lan, F., & Zha, X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.026 · Cited by 16
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.